VIA Pharmaceuticals, Inc.
VIAP
Rank in Stocks
#34455
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Share Price
$0.0005
Last synced: 2026-11-10
Market Cap
$10.23K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade VIA Pharmaceuticals, Inc. (VIAP)
Category
Healthcare
EPS for VIA Pharmaceuticals, Inc. (VIAP)
EPS as of December 2010 TTM: $-0.47
According to VIA Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-0.47. At the end of 2010 the company had an EPS of $-0.47, an increase over its 2009 EPS of $-1.05.
EPS history for VIA Pharmaceuticals, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.47 | 0.00% |
| 2010 | $-0.47 | -55.24% |
| 2009 | $-1.05 | 1.94% |
| 2008 | $-1.03 | -54.02% |
| 2007 | $-2.24 | 28.74% |
| 2006 | $-1.74 | -90.00% |
| 2005 | $-17.40 | 46.84% |
| 2004 | $-11.85 | -76.13% |
| 2003 | $-49.65 | -6.50% |
| 2002 | $-53.10 | 5.36% |
| 2001 | $-50.40 | 5.00% |
| 2000 | $-48.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $1.69 | -459.57% |
US
|
|
| $1.90 | -504.00% |
SE
|
|
| $6.83 | -1,554.17% |
FR
|
|
| $0.02 | -104.15% |
HK
|
|
| $2.81 | -698.09% |
IT
|
Questions about VIA Pharmaceuticals, Inc.'s earnings per share (EPS)
What is VIA Pharmaceuticals, Inc.'s earnings per share (EPS)?
VIA Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-0.47, as of Dec 2010.
What was VIA Pharmaceuticals, Inc.'s earnings per share (EPS) in 2010?
In 2010, VIA Pharmaceuticals, Inc.'s earnings per share (EPS) was $-0.47, compared with $-1.05 in 2009.
How has VIA Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2005?
From 2005 to 2010, VIA Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2010 ($-0.47) and lowest in 2005 ($-17.40).
How does VIA Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
VIA Pharmaceuticals, Inc.'s earnings per share (EPS) ($-0.47) is lower than that of all 5 similar companies listed above. The highest among them is Ipsen S.A., with $6.83.